Known targets — ChEMBL curated mechanism
POLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PRIM1PRIM2
The experimentally established mechanism targets of Cytidine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.90 |
| ▸ | MTOR | P42345 | 2/20 | 0.90 |
| ▸ | THRB | P10828 | 1/20 | 0.90 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.90 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.90 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.90 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.59 |
| ▸ | GMNN | O75496 | 1/20 | 0.59 |
| ▸ | TP53 | P04637 | 1/20 | 0.59 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.59 |
| ▸ | DNMT1 | P26358 | 1/20 | 0.59 |
| ▸ | THPO | P40225 | 1/20 | 0.59 |
| ▸ | HTT | P42858 | 1/20 | 0.59 |
| ▸ | RAB9A | P51151 | 1/20 | 0.59 |
| ▸ | BLM | P54132 | 1/20 | 0.59 |
| ▸ | HBB | P68871 | 1/20 | 0.59 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.59 |
| ▸ | P2RY2 | P41231 | 1/20 | 0.59 |
| ▸ | NT5E | P21589 | 1/20 | 0.57 |
| ▸ | TSHR | P16473 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Cytidine SCHEMBL1201153 | 1.00 | LMNA (0.90) | LMNAMTORTHRBMDM2NCOA1 | |
| Cytarabine SCHEMBL28898416 | 1.00 | LMNA (0.90) | LMNAMTORTHRBMDM2NCOA1 | |
| Cytarabine SCHEMBL458337 | 1.00 | LMNA (0.90) | LMNAMTORTHRBMDM2NCOA1 | |
| Cytarabine SCHEMBL9007590 | 1.00 | LMNA (0.90) | LMNAMTORTHRBMDM2NCOA1 | |
| Cytidine SCHEMBL39902 | 1.00 | LMNA (0.90) | LMNAMTORTHRBMDM2NCOA1 | |
| Cytarabine SCHEMBL285195 | 1.00 | LMNA (0.90) | LMNAMTORTHRBMDM2NCOA1 | |
| Cytidine SCHEMBL104628 | 1.00 | LMNA (0.90) | LMNAMTORTHRBMDM2NCOA1 | |
| Cytidine SCHEMBL6672407 | 0.99 | LMNA (0.88) | LMNAMTORTHRBMDM2NCOA1 | |
| Cytarabine SCHEMBL29084328 | 0.99 | LMNA (0.88) | LMNAMTORTHRBMDM2NCOA1 | |
| Cytidine SCHEMBL2370482 | 0.99 | LMNA (0.88) | LMNAMTORTHRBMDM2NCOA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1644394-B1 | SYNTHESIS AND COMPOSITIONS OF 2 -TERMINATOR NUCLEOTIDES | ROCHE DIAGNOSTICS GMBH (DE) | 2018-05-09 | — | — | EP | disclosed |
| EP-1641943-B1 | 2'-TERMINATOR NUCLEOTIDE-RELATED METHODS AND SYSTEMS | ROCHE DIAGNOSTICS GMBH (DE) | 2013-03-20 | — | — | EP | disclosed |
| US-8163487-B2 | 2′-terminator nucleotide-related methods and systems | ROCHE MOLECULAR SYSTEMS, INC. (US) | 2012-04-24 | — | — | US | disclosed |
| EP-2076606-B1 | 2'-TERMINATOR RELATED PYROPHOSPHOROLYSIS ACTIVATED POLYMERIZATION | ROCHE DIAGNOSTICS GMBH (DE) | 2012-01-25 | — | — | EP | disclosed |
| US-20110201002-A1 | 2'-Terminator Nucleotide-Related Methods and Systems | ROCHE MOLECULAR SYSTEMS, INC. (US) | 2011-08-18 | — | — | US | disclosed |
| US-7947817-B2 | Nucleotide blocked with sugar compound; biosynthesis of nucleic acids | ROCHE MOLECULAR SYSTEMS, INC. (US) | 2011-05-24 | — | — | US | disclosed |
| US-7928207-B2 | use of 2'-terminator nucleotides to effect chain termination; kits; incubating a template nucleic acid with a nucleotide incorporating biocatalyst, and a 2'-terminator nucleotide | ROCHE MOLECULAR SYSTEMS, INC (US) | 2011-04-19 | — | — | US | disclosed |
| US-7919249-B2 | use of 2'-terminator nucleotides to effect chain termination; kits; incubating a template nucleic acid with a nucleotide incorporating biocatalyst, and a 2'-terminator nucleotide | ROCHE MOLECULAR SYSTEMS, INC. (US) | 2011-04-05 | — | — | US | disclosed |
| US-7745125-B2 | 2′-terminator related pyrophosphorolysis activated polymerization | ROCHE MOLECULAR SYSTEMS, INC. (US) | 2010-06-29 | — | — | US | disclosed |
| EP-2195327-A2 | SYNTHESIS AND COMPOSITIONS OF NUCLEIC ACIDS COMPRISING 2'-TERMINATOR NUCLEOTIDES | Roche Diagnostics GmbH (DE) | 2010-06-16 | — | — | EP | disclosed |
| WO-2008046609-A2 | SYNTHESIS AND COMPOSITIONS OF NUCLEIC ACIDS COMPRISING 2'-TERMINATOR NUCLEOTIDES | ROCHE DIAGNOSTICS GMBH (DE) | 2008-04-24 | — | — | WO | disclosed |
| US-20070219361-A1 | Synthesis and compositions of nucleic acids comprising 2'-terminator nucleotides | ROCHE MOLECULAR SYSTEMS, INC. (US) | 2007-09-20 | — | — | US | disclosed |
| US-20070154914-A1 | 2'-Terminator related pyrophosphorolysis activated polymerization | ROCHE MOLECULAR SYSTEMS, INC. (US) | 2007-07-05 | — | — | US | disclosed |
| EP-1644394-A2 | SYNTHESIS AND COMPOSITIONS OF 2 -TERMINATOR NUCLEOTIDES | Roche Diagnostics GmbH (DE) | 2006-04-12 | — | — | EP | disclosed |
| EP-1641943-A2 | 2'-TERMINATOR NUCLEOTIDE-RELATED METHODS AND SYSTEMS | Roche Diagnostics GmbH (DE) | 2006-04-05 | — | — | EP | disclosed |
| WO-2005026184-A9 | SYNTHESIS AND COMPOSITIONS OF 2'-TERMINATOR NUCLEOTIDES | ROCHE DIAGNOSTICS GMBH (DE) | 2006-03-02 | — | — | WO | disclosed |
| WO-2005026184-A2 | SYNTHESIS AND COMPOSITIONS OF 2'-TERMINATOR NUCLEOTIDES | ROCHE DIAGNOSTICS GMBH (DE) | 2005-03-24 | — | — | WO | disclosed |
| US-20050037398-A1 | 2'-terminator nucleotide-related methods and systems | ROCHE MOLECULAR SYSTEMS, INC. (US) | 2005-02-17 | — | — | US | disclosed |
| US-20050037991-A1 | Synthesis and compositions of 2'-terminator nucleotides | ROCHE MOLECULAR SYSTEMS, INC. (US) | 2005-02-17 | — | — | US | disclosed |
| WO-2005005667-A2 | 2'-TERMINATOR NUCLEOTIDE-RELATED METHODS AND SYSTEMS | ROCHE DIAGNOSTICS GMBH (DE) | 2005-01-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050037991-A1 | Synthesis and compositions of 2'-terminator nucleotides | RNGTT, NT5C3B, NSUN2 | LMNA 1378/4885MTOR 3329/4885THRB 1065/4885 |
| US-20070219361-A1 | Synthesis and compositions of nucleic acids comprising 2'-terminator nucleotides | RNGTT, POLRMT, NT5C3B | LMNA 684/4885MTOR 4854/4885THRB 683/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.